Related Experiment Video
Updated: Jun 4, 2026
09:33
Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis
Published on: March 20, 2026
Targeting apoptosis pathways in glioblastoma
Günter Eisele1, Michael Weller
1Department of Neurology, University Hospital Zurich, Frauenklinikstrasse 26, CH-8091 Zurich, Switzerland. guenter.eisele@usz.ch
Cancer Letters
|January 29, 2011
Summary
Glioblastoma treatment is challenging due to resistance to therapies. This review explores targeting apoptosis pathways, like p53 and BCL-2, to improve glioblastoma patient outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Glioblastoma is a highly aggressive brain tumor with significant resistance to conventional radio- and chemotherapy.
- Altered apoptosis pathways in glioblastoma cells contribute to their resistance against apoptotic stimuli.
Purpose of the Study:
- To review alterations in key apoptosis-regulating pathways in glioblastoma.
- To identify potential therapeutic targets within these pathways for glioblastoma treatment.
- To explore strategies for enhancing glioblastoma cell susceptibility to death receptor-mediated apoptosis.
Main Methods:
- Review of scientific literature on glioblastoma apoptosis pathways.
- Analysis of alterations in the p53 pathway, BCL-2 protein family, and inhibitor of apoptosis proteins.
- Examination of growth factor pathways regulating programmed cell death.
- Evaluation of strategies targeting death receptor pathways.
Main Results:
- Specific alterations in the p53 pathway, BCL-2 family, and IAP proteins contribute to glioblastoma's apoptotic resistance.
- Several pre-clinical strategies targeting apoptosis pathways show promise for glioblastoma therapy.
- Targeting death receptor pathways may sensitize glioblastoma cells without increasing general toxicity.
Conclusions:
- Targeting apoptosis pathways represents a promising therapeutic avenue for glioblastoma.
- Further research and development of these pre-clinical strategies are crucial for improving glioblastoma patient outcomes.
- Modulating programmed cell death mechanisms offers a potential strategy to overcome therapeutic resistance in glioblastoma.
Related Concept Videos
01:31The Intrinsic Apoptotic Pathway
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:17The Extrinsic Apoptotic Pathway
The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...